Cargando…

Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer

Breast cancer is a heterogeneous disease, and the different biological subtypes have different prognostic impacts. Neoadjuvant trials have recently become popular as they offer several advantages compared to traditional adjuvant trials. Studies have shown that patients who achieve pathological compl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pennisi, Angela, Kieber-Emmons, Thomas, Makhoul, Issam, Hutchins, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2016
Materias:	Short Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961053/ https://www.ncbi.nlm.nih.gov/pubmed/27478380 http://dx.doi.org/10.4137/BCBCR.S33163

Ejemplares similares

Breast Cancer Immunotherapy: An Update
por: Makhoul, Issam, et al.
Publicado: (2018)

Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
por: Hutchins, Laura F., et al.
Publicado: (2017)

Breast cancer survival disparity between African American and Caucasian women in Arkansas: A race-by-grade analysis
por: Monzavi-Karbassi, Behjatolah, et al.
Publicado: (2016)

Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
por: Hsu, Ping-Ching, et al.
Publicado: (2020)

Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study
por: Hernandez Puente, Cinthia Violeta, et al.
Publicado: (2020)

P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
por: Makhoul, Issam, et al.
Publicado: (2021)

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
por: Müller, Carolin, et al.
Publicado: (2021)

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
por: Huober, Jens, et al.
Publicado: (2023)

Clinical and Therapeutic Factors Vary by Prognosis in Patients with Pathological Complete Response After Neoadjuvant Therapy for Breast Cancer
por: Huang, Zhenfeng, et al.
Publicado: (2021)

Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
por: Ferrari, Linda, et al.
Publicado: (2015)

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015)

Pathological Complete Response in Locally Advanced Breast Cancer after Neoadjuvant Chemotherapy: Survival Outcome and Its Relevance as a Surrogate End Point
por: Agarwal, Reshu, et al.
Publicado: (2020)

Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy
por: Cui, Jian, et al.
Publicado: (2016)

Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer
por: Todorova, Valentina K., et al.
Publicado: (2022)

Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
por: Tanioka, M, et al.
Publicado: (2010)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

Pathologic Evaluation of Breast Cancer after Neoadjuvant Therapy
por: Park, Cheol Keun, et al.
Publicado: (2016)

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients
por: Makhoul, Issam, et al.
Publicado: (2017)

Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data
por: Walbaum, Benjamín, et al.
Publicado: (2021)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer
por: Silva, Luana Carolina Ferreira Fiuza, et al.
Publicado: (2019)

Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia
por: Rodríguez, Mauricio, et al.
Publicado: (2023)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
por: Sasanpour, Pegah, et al.
Publicado: (2018)

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
por: Guiu, S, et al.
Publicado: (2010)

Carbohydrate Mimetic Peptides Augment Carbohydrate-Reactive Immune Responses in the Absence of Immune Pathology
por: Hennings, Leah, et al.
Publicado: (2011)

Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years
por: McFarland, Daniel C., et al.
Publicado: (2016)

Pathological Complete Response After Neoadjuvant Therapy in Rectal Adenocarcinoma: a 5-Year Follow-up
por: Leow, Yeen Chin, et al.
Publicado: (2021)

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
por: Fujii, Takeo, et al.
Publicado: (2017)

Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review
por: Chainitikun, Sudpreeda, et al.
Publicado: (2021)

Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy
por: Qian, Xiaoyan, et al.
Publicado: (2022)

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
por: Tostes, Francinne T., et al.
Publicado: (2022)

Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient's Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis
por: Liu, Hui, et al.
Publicado: (2021)

Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response
por: Xu, Yinggang, et al.
Publicado: (2023)

A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer
por: Shi, Wenjie, et al.
Publicado: (2022)

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
por: KAWAJIRI, HIDEMI, et al.
Publicado: (2014)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response
por: Resende, Uanderson, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4nc6ca2usvhvm2l8cl8o4r5v7v